,0
symbol,XBIO
price,0.8543
beta,2.38755
volAvg,233800
mktCap,5378869
lastDiv,0.0
range,0.44-1.85
changes,0.0243
companyName,Xenetic Biosciences Inc
currency,USD
cik,0001534525
isin,US9840155033
cusip,984015503
exchange,NASDAQ Capital Market
exchangeShortName,NASDAQ
industry,Biotechnology
website,https://www.xeneticbio.com/
description,"Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 7 full-time employees. The firm is focused on progressing XCART, a personalized chimeric antigen receptor (CAR) T platform technology engineered to target patient-specific tumor neoantigens. The firm is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patientâ€™s malignant tumor cells for the treatment of B-cell lymphomas. The firm is leveraging PolyXen, its drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen enables biological drugs by modifying their half-life and other pharmacological properties."
ceo,Mr. Jeffrey Eisenberg
sector,Healthcare
country,US
fullTimeEmployees,4
phone,17817787720
address,40 Speen St Ste 102
city,Framingham
state,MASSACHUSETTS
zip,01701
dcfDiff,-1.54
dcf,0.0
image,https://financialmodelingprep.com/image-stock/XBIO.png
ipoDate,2016-11-07
defaultImage,False
